Kadimastem - Stem Cell to Cure Diseases

About Us > Management Team

Yossi Ben-Yossef

Yossi Ben-Yossef - CEO

Mr. Ben-Yossef co-founded Kadimastem in 2009, along with Prof. Michel Revel. Prior to Kadimastem, he has been leading investments and taking an active role in successful Biotech/Life Sciences companies in the last 12 years. Among the companies he was involved with are Evogen (TASE: EVGN), VBL (NASDAQ:VBLT), and Biondvax (TASE: BNDX). 

 

Prof. Michel Revel, MD, PhD

Prof. Michel Revel, MD, PhD - Chief Scientist

Prof. Revel is Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. His research on Interferon, its mechanisms of action and the isolation of the human Interferon-beta gene, have led to the development of Interferon-beta therapy for the treatment of multiple sclerosis, Rebif®, Blockbuster drug marketed worldwide.

In recent years, Prof. Revel's laboratory focused on hESC and succeeded to produce nerve myelinating cells that, when transplanted in myelin-deficient animals, have regenerated the myelin coating. These studies contributed to the development of a suspension culture technology for hESC which can then be used to produce differentiated human cells such as insulin-producing pancreatic beta cells and nerve myelinating cells.

Alongside his research and development activity, Prof. Revel is deeply involved in the ethics of science and biotechnology, and served as chairman of the Israel National Bioethics Council, and was a member of the International Bioethics Committee of UNESCO.

Prof. Revel was the recipient of the Israel Prize for medical research, the EMET Prize for biotechnology, and is a member of the Israel Academy of Science and Humanities. He has been a member of Israel's National Committee for Biotechnology, serving for three years as its chairman.

 

Arik Hasson, PhD

Arik Hasson, PhD - Executive VP Research and Development

Dr. Hasson was Kadimastem ’s first employee when it was founded in fall of 2009. Prior to Kadimastem, Dr. Hasson was the head of Stem Cell Projects in Gamida Cell, a stem cell therapeutic company. While at Gamida Cell, Dr. Hasson also headed the diabetic and neurological projects.
In addition, Dr. Hasson helped to initiate and served as the R&D Director of the Israeli Consortium for Stem Cells R&D (“Bereshit”), a consortium funded by the Chief Scientist in the Israeli Office of Industry, Trade & Labor. Prior to these roles, Dr. Hasson was head of Development in Gamida Cell and helped developing its first Cell Therapy product, StemEx® into clinical trial (Currently completing phase III clinical trials for treatment of hematological malignancies).
Dr. Hasson holds a PhD in cellular neurobiology from the Hebrew University of Jerusalem, and did a post-doctoral research in the Biotechnology Laboratory, University of British Columbia, Vancouver, BC, Canada. He is the author of tens of peered review papers in the fields of stem cell, cell therapy and neurobiology and of 17 patents in these fields.

 

Yehuda Feinberg

Yehuda Feinberg - Chief Financial Officer

Yehuda Feinberg has over 20 years of financial and operational management experience in the biotech, high-tech and telecom sectors, both in startup companies and in large, established companies. Mr. Feinberg has worked with several startup companies in financial managment positions as well as in a consultancy capacity in business planning and financial modeling. Mr. Feinberg served as VP Finance for Rosetta Genomics Ltd. (NASDAQ:ROSG), a biotech startup company and for Roqiya Networks, a hi-tech startup in the field of free-space optical communications. Between 2006 and 2010 Mr. Feinberg served as Corporate Director of Financial Planning and Analysis for NICE Systems Ltd.( NASDAQ: NICE), a leading global hi-tech company. Previously Mr. Feinberg served as Director of Economics and Budgets at Pelephone Communications, Israel's first cellular operator. Mr. Feinberg has a BA in Economics from Rutgers University and an MBA from the Hebrew University of Jerusalem.

 

Michal Izrael, PhD

Michal Izrael, PhD - VP Research and Development for ALS and Neurodegenerative Diseases

Dr. Izrael Joined Kadimastem in 2009. Prior to joining Kadimastem, as part of her doctoral work at the Weizmann Institute of Science in the laboratory of Prof. Revel, Dr. Izrael was a central part of the team that invented and developed the technology which became the basis for Kadimastem’s cell therapy product for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. At Kadimastem she served as the head of the drug screening team, based on human oligodendrocytes (Myeling forming cells), and in 2012 was appointed to run the neurodegenerative department at Kadimastem, responsible for Kadimastem’s cell product for ALS. In 2017 she was appointed as VP for Research and Development for ALS and Neurodegenerative Diseases. Dr. Izrael holds a PhD in molecular genetics from the Weizmann Institute of Science and M.Sc. in Neurobiology from the Hebrew University of Jerusalem. Dr. Izrael has published 16 scientific papers and patents in the field of neurobiology and development of technologies based on stem cell derivatives for the treatment of central nervous system disease and drug screening.